{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-014293","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2025-09-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.391693+00:00","generated_at":"2026-05-17T06:08:59.399724+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Calidi eliminates CLO role; W. Pizarro Campbell departs Oct 17, 2025","bullets":["CLO position eliminated; Campbell's employment terminated Oct 17, 2025 as part of cost-reduction initiatives; no disagreement cited.","Campbell receives severance of $212,500 paid over six months, plus potential $85,000 bonus tied to Nova Cell transaction before Oct 31, 2025.","Campbell enters six-month consulting agreement at $250/hr (max 20 hrs/mo) starting Oct 18, 2025.","CFO Andrew Jackson appointed as Corporate Secretary effective Oct 17, 2025.","Separation agreement includes standard release, confidentiality, and non-disparagement clauses."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-014293","json":"https://secwatch.observer/filing/0001493152-25-014293.json","markdown":"https://secwatch.observer/filing/0001493152-25-014293.md","text":"https://secwatch.observer/filing/0001493152-25-014293.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000149315225014293/0001493152-25-014293-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000149315225014293/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:08:59.399724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}